Slide 1: Clinical Stage Antiviral Drug Development Company
BIOTRON LIMITED (ASX:BIT) Clinical Stage An;viral Drug Development Company Michelle Miller CEO & Managing Director +61 (0) 412 313 329 mmiller@biotron.com.au
Slide 2: Forward Looking Statements
Forward Looking Statements This presenta,on may contain forward-‐looking statements with respect to the financial condi,on, results and business achievements/performance of Biotron Limited and certain of the plans and objec,ves of its management. These statements are statements that are not historic
Slide 3: Biotron Limited Overview
Biotron Limited Overview • Clinical stage antiviral drug development company • Focus on developing novel small molecule drugs • Clinical programs for Hepatitis C virus (HCV) and HIV • Earlier stage programs include Dengue and others • Headquartered in Sydney, Australia • Key recent highlights • Mar
Slide 4: Biotron - Advanced Pipeline of Clinical Programs
Biotron -‐ Advanced Pipeline of Clinical Programs VIRAL INDICATION DISCOVERY PRE-‐CLINICAL PHASE 1a PHASE 1b PHASE 2a PHASE 2b STATUS TARGET • Ph 2a complete; • Ph 2b (3 mth Hepa;;s C p7 dosing) scheduled for 4Q13 HIV Vpu • Ph 2a complete Hepa;;s C/ Vpu/p7 • Ph 2 in progress HIV Dengue M Next • Re
Slide 5: BIT225 and Hepatitis C
BIT225 and Hepa;;s C • New investigational oral drug for treating HCV infection • First in class; targets p7 protein – essential for virus assembly and release • Synergistic with IFN/RBV (current treatment) and polymerase inhibitors • Three completed trials: § Phase Ia –Single dose, dose-escalating
Slide 6: BIT225 HCV Phase 2 Clinical Information
BIT225 HCV Phase 2 Clinical Informa;on % with End of % with Early Treatment Viroogical Median log Virological Response Treatment reduc;on at Response 35 days (<50IU/ml at 12 Treatment window (<50IU/ml at 48 weeks) weeks) 400 mg BIT225 + -‐4.957 86 100 IFN/RBV 200 mg BIT225 + -‐4.351 88 88 IFN/RBV
Slide 7: BIT225 and HIV
BIT225 and HIV • BIT225 also has potent anti-HIV activity – Unique mode of action targets HIV “hiding” in long-lived reservoir cells • Reservoirs are last of the holy grail in HIV * • No existing drugs target this source of HIV in the body • Phase 2a trial of BIT225 in HIV-infected subjects recently
Slide 8: Biotron Opportunity
Biotron Opportunity • Documented need for new antiviral drugs • Licensing space is very active (Gilead/Pharmasset US$11b deal) • HCV worldwide market ~US$2.8 billion; predicted to reach >US$10 billion • BIT225 - good clinical efficacy against both HCV and HIV • Potential use with new (DAA) or existi
Slide 9: Key Financials and Facts
Key Financials and Facts BIOTRON ASX Code LIMITED KEY FINANCIALS price BIT history chart Mr Michael Hoy BOARD AND MANAGEMENT Chairman Recent Share Price (30 May 2013) A$0.10 Dr Michelle Miller CEO & Managing Director 52 Week High A$0.185 Dr Denis Wade Non-‐Execu;ve Director 52 Week Low A$0.08 Dr Su